Press Releases

Press Releases

Date Title Views
March 18, 2019
AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic indicator of survival in ATTR-CM patients, in all mutant and wild-type subjects.
March 11, 2019
SAN FRANCISCO , March 11, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq: EIDX ) today announced that management is scheduled to participate in a fireside chat regarding Eidos at the 31 st Annual ROTH Conference on Monday, March 18 th at 8:30 a.m. PDT in Orange County, CA.
February 27, 2019
ATTRibute-CM study design, which incorporates feedback from the FDA , has the potential to accelerate registration with a 12-month primary endpoint of change in 6-minute walk distance (6MWD), followed by a 30-month endpoint of mortality and cardiovascular-related hospitalizations Trial sites
February 25, 2019
SAN FRANCISCO , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it will host an investor webcast
February 21, 2019
SAN FRANCISCO , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present at two upcoming investor conferences. SVB Leerink Global Healthcare Conference The company will present on Thursday, February 28 , 2019 at 11:00 a.m. ET.
January 2, 2019
SAN FRANCISCO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9 th at 4:30 p.m. PST in San Francisco, CA.